Medications

Japan first nation to approve Novartis psoriasis drug

Swiss pharmaceutical company Novartis said Friday it has won approval to market its Cosentyx psoriasis treatment in Japan, making it the first country to authorise commercialisation of the drug.

Medications

Novartis Japan admits concealing drug side effects

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Diseases, Conditions, Syndromes

Novartis licences drugs to non-profit TB group

Swiss-based pharmaceuticals giant Novartis said Wednesday that it had signed a licensing deal with an international organisation that fights tuberculosis.

Medications

Novartis to use Google technology for eye care

Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease.

Medications

Novartis Japan unit charged over research manipulation

Japanese prosecutors Tuesday laid charges against the local unit of Swiss pharmaceutical giant Novartis in a widening scandal over claims that falsified data were used to exaggerate the benefits of a popular blood-pressure ...

Medications

Novartis reshapes business with GSK, Lilly deals (Update)

Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that heralds more ...

Alzheimer's disease & dementia

New Japan research scandal brewing over Alzheimer's study

Japan's health ministry said Friday it was probing claims falsified data was used in an Alzheimer's disease study involving major pharmaceutical firms, a day after filing an unrelated criminal complaint against Swiss drugs ...

page 3 from 16